ICE Medinice S.A.
Medinice S.A., a medical technology company, creates, develops, and commercializes minimally invasive solutions in cardiology and cardiac surgery. The company offers PacePress, a medical device to reduce the risk of complications following the implantation of cardiac electrotherapeutic devices, such as pacemakers or implantable cardioverter-defibrillators; CoolCryo, a cardiac cryoablation technology that uses liquid nitrogen as the cooling medium; and AtriClamp, a clip designed to close the left atrial appendage to minimize the risk of stroke in patients with atrial fibrillation. It also provides MiniMax, an ablation-mapping catheter used for detecting intracardiac electrophysiological signals, creating a 3D map of the heart, and performing intracardiac irrigated RF ablation to treat arrhythmias caused by abnormalities in the heart's conduction system; and EP Bioptom, an electrode for endomyocardial biopsy using 3D mapping enabling simultaneous biopsy and creation of a three-dimensional heart map. The company was founded in 2012 and is headquartered in Warsaw, Poland.…
Industry Peers
Medical DevicesKey Statistics
About Medinice (WSE: ICE)
›
Medinice (WSE: ICE) is listed on Warsaw Stock Exchange, where its shares trade in PLN. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 12 employees.
The shares were at 44.50 PLN on 20 November 2026, up 287.6% over 52 weeks. Its 52-week range is 10.14 PLN to 95.10 PLN: the price is 53.2% below the high and 338.9% above the low.
Its market capitalisation is 465.10M PLN.
Medinice reports return on equity of -7.6% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 3.67M PLN. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.